The emerging role of PRMT6 in cancer

Z Chen, J Gan, Z Wei, M Zhang, Y Du, C Xu… - Frontiers in …, 2022 - frontiersin.org
Protein arginine methyltransferase 6 (PRMT6) is a type I PRMT that is involved in epigenetic
regulation of gene expression through methylating histone or non-histone proteins, and …

Base excision repair: mechanisms and impact in biology, disease, and medicine

D Gohil, AH Sarker, R Roy - International Journal of Molecular Sciences, 2023 - mdpi.com
Base excision repair (BER) corrects forms of oxidative, deamination, alkylation, and abasic
single-base damage that appear to have minimal effects on the helix. Since its discovery in …

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours

AR Green, MA Aleskandarany, D Agarwal… - British journal of …, 2016 - nature.com
Background: MYC is amplified in approximately 15% of breast cancers (BCs) and is
associated with poor outcome. c-MYC protein is multi-faceted and participates in many …

[HTML][HTML] Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer

TMA Abdel-Fatah, R Russell, N Albarakati… - Molecular …, 2014 - Elsevier
FEN1 has key roles in Okazaki fragment maturation during replication, long patch base
excision repair, rescue of stalled replication forks, maintenance of telomere stability and …

[HTML][HTML] Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer

TMA Abdel-Fatah, FK Middleton, A Arora, D Agarwal… - Molecular …, 2015 - Elsevier
ATR-CHEK1 signalling is critical for genomic stability. ATR-CHEK1 signalling may be
deregulated in breast cancer and have prognostic, predictive and therapeutic significance …

The current status of DNA-repair-directed precision oncology strategies in epithelial ovarian cancers

H Tang, S Kulkarni, C Peters, J Eddison… - International Journal of …, 2023 - mdpi.com
Survival outcomes for patients with advanced ovarian cancer remain poor despite advances
in chemotherapy and surgery. Platinum-based systemic chemotherapy can result in a …

Inhibition of DNA repair in cancer therapy: toward a multi-target approach

S Lodovichi, T Cervelli, A Pellicioli, A Galli - International journal of …, 2020 - mdpi.com
Alterations in DNA repair pathways are one of the main drivers of cancer insurgence.
Nevertheless, cancer cells are more susceptible to DNA damage than normal cells and they …

[HTML][HTML] Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy

N Albarakati, TMA Abdel-Fatah, R Doherty, R Russell… - Molecular …, 2015 - Elsevier
BRCA1, a key factor in homologous recombination (HR) repair may also regulate base
excision repair (BER). Targeting BRCA1-BER deficient cells by blockade of ATM and DNA …

Defective base excision repair in the response to DNA damaging agents in triple negative breast cancer

KJ Lee, CG Piett, JF Andrews, E Mann, ZD Nagel… - PLoS …, 2019 - journals.plos.org
DNA repair defects have been increasingly focused on as therapeutic targets. In hormone-
positive breast cancer, XRCC1-deficient tumors have been identified and proposed as …

Evolving DNA repair synthetic lethality targets in cancer

S Kulkarni, J Brownlie, JN Jeyapalan… - Bioscience …, 2022 - portlandpress.com
DNA damage signaling response and repair (DDR) is a critical defense mechanism against
genomic instability. Impaired DNA repair capacity is an important risk factor for cancer …